Journal Article

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Evans, T R Jeffry, Dutcus, Corina, Ren, Min, Kudo, Masatoshi, Jassem, Jacek, Park, Joong-Won, Piscaglia, Fabio, Kraljevic, Silvija, Baron, Ari, Cheng, Ann-Lii, Qin, Shukui, Finn, Richard S, Han, Kwang-Hyub, Guo, Matthew, Ikeda, Kenji, Han, Guohong, Komov, Dmitry, Vogel, Arndt, Saito, Kenichi, Blanc, Jean Frederic, Tamai, Toshiyuki, Lopez, Carlos

2018

Overview

In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors 1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Patients were randomly assigned (1:1) via an interactive voice–web response system—with region; macroscopic portal vein invasion, extrahepatic spread, or both; Eastern Cooperative Oncology Group performance status; and bodyweight as stratification factors—to receive oral lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg) or sorafenib 400 mg twice-daily in 28-day cycles. The primary endpoint was overall survival, measured from the date of randomisation until the date of death from any cause. The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. The non-inferiority margin was set at 1·08. The trial is registered with ClinicalTrials.gov, number NCT01761266. Between March 1, 2013 and July 30, 2015, 1492 patients were recruited. 954 eligible patients were randomly assigned to lenvatinib (n=478) or sorafenib (n=476). Median survival time for lenvatinib of 13·6 months (95% CI 12·1–14·9) was non-inferior to sorafenib (12·3 months, 10·4–13·9; hazard ratio 0·92, 95% CI 0·79–1·06), meeting criteria for non-inferiority. The most common any-grade adverse events were hypertension (201 [42%]), diarrhoea (184 [39%]), decreased appetite (162 [34%]), and decreased weight (147 [31%]) for lenvatinib, and palmar-plantar erythrodysaesthesia (249 [52%]), diarrhoea (220 [46%]), hypertension (144 [30%]), and decreased appetite (127 [27%]) for sorafenib. Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability profiles of lenvatinib were consistent with those previously observed. Eisai Inc.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Aged / Antineoplastic Agents - therapeutic use / Cancer therapies / Carcinoma, Hepatocellular - drug therapy / Carcinoma, Hepatocellular - mortality / Chemotherapy / Clinical trials / Disease / Disease control / Drug dosages / Evidence-based medicine / Fatalities / Female / Hepatocellular carcinoma / Hepatology / Humans / Inhibitor drugs / Liver / Liver cancer / Liver cirrhosis / Liver Neoplasms - drug therapy / Liver Neoplasms - mortality / Male / Middle Aged / Niacinamide - analogs & derivatives / Niacinamide - therapeutic use / Phenylurea Compounds - therapeutic use / Questionnaires / Quinolines - therapeutic use / Sorafenib / Survival / Survival Rate / Targeted cancer therapy / Treatment Outcome / Tumors